Literature DB >> 10469077

Sclerotherapy for leg telangiectasia--a blinded comparative trial of polidocanol and hypertonic saline.

S McCoy, A Evans, N Spurrier.   

Abstract

BACKGROUND: Hypertonic saline (HS) and polidocanol (POL) have been in use around the world for sclerotherapy of telangiectasia for many years. However, despite numerous articles in the literature extolling the virtues of their individual use, few studies scientifically compare their relative efficacies.
OBJECTIVE: To compare, in a statistically significant number of female patients, the relative efficacy of hypertonic saline and polidocanol as sclerosants of leg telangiectasia and reticular feeding veins, using each patient as her own control.
METHODS: Eighty-one women with roughly matching leg telangiecasia were treated with sclerotherapy. One leg was injected with 20% saline/2% lignocaine, the other with 1% polidocanol, with the patients blinded as to the sclerosant used for each leg. Assessment of percent reduction of vessels, and the complications of matting and hemosiderin staining was conducted at 2 months by 3 methods: the patient's satisfaction, the treating physician's evaluation, and blinded assessment of before and after photographs.
RESULTS: There was no statistically significant difference between HS and POL treated legs when assessed clinically or photographically. However, POL caused more staining and matting, and despite patients finding HS more painful at injection, patient satisfaction at follow-up was higher with the HS treated leg.
CONCLUSION: 20% HS and 1% POL have equal efficacy in sclerosing leg telangiectasia and reticular feeding veins. POL causes more adverse sequelae, although these may be related to the solution concentration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469077     DOI: 10.1046/j.1524-4725.1999.08263.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  6 in total

Review 1.  [Sclerotherapy for varicosities].

Authors:  F Pannier; E Rabe
Journal:  Hautarzt       Date:  2006-01       Impact factor: 0.751

Review 2.  Treatment for telangiectasias and reticular veins.

Authors:  Luis Cu Nakano; Daniel G Cacione; Jose Cc Baptista-Silva; Ronald Lg Flumignan
Journal:  Cochrane Database Syst Rev       Date:  2021-10-12

3.  Sclerotherapy for Reticular Veins in the Lower Limbs: A Triple-Blind Randomized Clinical Trial.

Authors:  Matheus Bertanha; Rodrigo Gibin Jaldin; Regina Moura; Rafael Elias Farres Pimenta; Jamil Victor de Oliveira Mariúba; Carlos Eduardo Pinheiro Lúcio Filho; Giovana Piteri Alcantara; Carlos Roberto Padovani; Winston Bonetti Yoshida; Marcone Lima Sobreira
Journal:  JAMA Dermatol       Date:  2017-12-01       Impact factor: 10.282

Review 4.  Sclerotherapy for lower limb telangiectasias.

Authors:  Lisa Schwartz; Heather Maxwell
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

5.  Polidocanol versus hypertonic glucose for sclerotherapy treatment of reticular veins of the lower limbs: study protocol for a randomized controlled trial.

Authors:  Matheus Bertanha; Marcone Lima Sobreira; Carlos Eduardo Pinheiro Lúcio Filho; Jamil Victor de Oliveira Mariúba; Rafael Elias Farres Pimenta; Rodrigo Gibin Jaldin; Andrei Moroz; Regina Moura; Hamilton Almeida Rollo; Winston Bonetti Yoshida
Journal:  Trials       Date:  2014-12-19       Impact factor: 2.279

6.  Polidocanol versus glucose in the treatment of telangiectasia of the lower limbs (PG3T): Protocol for a randomized, controlled clinical trial.

Authors:  Matheus Bertanha; Paula Angeleli Bueno de Camargo; Regina Moura; Winston Bonetti Yoshida; Rafael Elias Farres Pimenta; Jamil Victor de Oliveira Mariúba; Giovana Piteri Alcantara; Dênia Reis de Paula; Marcone Lima Sobreira
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.